The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Rachel Humphrey named chief medical officer of CytomX

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

RACHEL HUMPHREY was named chief medical officer of CytomX. Humphrey previously served as a member of the company’s board of directors.

Humphrey formerly led immuno-oncology at Eli Lilly and AstraZeneca, and also oversaw clinical development of Yervoy (ipilmumab) at Bristol-Myers Squibb and the development of Nexavar (sorafenib) at Bayer.

Humphrey recently held positions as vice president and head of immuno-oncology at Eli Lilly and at AstraZeneca, where she was responsible for building the immuno-oncology departments and supervising the strategies and designs for all the immuno-oncology agents in development.

She previously served as vice president of product development at Bristol-Myers Squibb, where she led all aspects of the clinical development of Yervoy through the submission of global biologics license applications and global launch.

At Bayer, Humphrey supervised the early and late stage clinical development of Nexavar for treatment of renal cell carcinoma. She began her career as an oncology fellow and staff physician at the NCI.

In connection with her appointment as chief medical officer, Humphrey will resign from the board of directors of CytomX.

Table of Contents

YOU MAY BE INTERESTED IN

Clinical

Oncofertility coverage mandates expand to 21 states and DC as political momentum builds
Gaps persist as patients face harrowing decisions and huge copays

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

By Claire Marie Porter and Sara Willa Ernst
Guest Editorial

My introduction to, and lessons learned from, Rick Pazdur

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
By Mikkael A. Sekeres
Sponsored

Meeting the moment: ASCO GI Cancers Symposium delivers insights and collaboration

When it comes to fighting cancer today, collaboration is key. At a time when funding is uncertain, yet innovative breakthroughs are accelerating every day, it’s more important than ever for oncologists, scientists, academic researchers, and community physicians, to come together to share knowledge and gain insights about the forefront of cancer research.
By The American Society of Clinical Oncology
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account